Literature DB >> 30635931

HIF1A-AS2 predicts poor prognosis and regulates cell migration and invasion in triple-negative breast cancer.

Yufei Wang1, Guochao Zhang1, Jie Han1.   

Abstract

The aberrant expression of hypoxia-inducible factor 1 alpha (HIF1A)-antisense RNA 2 (HIF1A-AS2) was found in various human cancers including breast cancer. The aim of this study was to present more evidence about the role HIF1A-AS2 on triple-negative breast cancer (TNBC). In our results, HIF1A-AS2 was also found to be upregulated in TNBC tissues compared with non-TNBC tissues or adjacent normal tissues. Besides, HIF1A-AS2 expression was also elevated in TNBC cell lines compared with the normal breast epithelial cell line. Moreover, high expression of HIF1A-AS2 was associated with lymph node metastasis, distant metastasis and unfavorable histological grade in TNBC patients. Survival analysis showed a TNBC patient with high HIF1A-AS2 expression had shorter overall survival than patients with low HIF1A-AS2 expression, and HIF1A-AS2 high expression acted as an independent poor prognostic factor for overall survival in TNBC patients. The cell migration and invasion assays suggested inhibition of HIF1A-AS2 obviously depressed TNBC cell migration and invasion. In conclusion, HIF1A-AS2 serves as a novel biomarker for predicting clinical progression and prognosis in TNBC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  biomarker; breast cancer; hypoxia-inducible factor 1 alpha (HIF1A)-antisense RNA 2 (HIF1A-AS2); long noncoding RNA (lncRNA)

Year:  2019        PMID: 30635931     DOI: 10.1002/jcb.28337

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

Review 1.  Metabolism and immunity in breast cancer.

Authors:  Deyu Zhang; Xiaojie Xu; Qinong Ye
Journal:  Front Med       Date:  2020-10-19       Impact factor: 4.592

Review 2.  The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.

Authors:  Utpalendu Paul; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-03-02       Impact factor: 2.742

3.  Long Noncoding RNA HIF1A-AS2 Promotes Non-Small Cell Lung Cancer Progression by the miR-153-5p/S100A14 Axis.

Authors:  Weiqiang Zhang; Keqiang Liu; Yingxin Pei; Jian Tan; Jingbo Ma; Jing Zhao
Journal:  Onco Targets Ther       Date:  2020-08-26       Impact factor: 4.147

4.  lncRNAHIF1A-AS2 Promotes Renal Carcinoma Cell Proliferation and Migration via miR-130a-5p/ERBB2 Pathway.

Authors:  Yunxiao Zhu; Ziyi Yang; Han Chen; Yang Pan; Lifeng Gong; Falin Chen; Xiaoxiang Jin; Shuang Wen; Yi Li; Gang Chen
Journal:  Onco Targets Ther       Date:  2020-10-01       Impact factor: 4.147

5.  Anti-Proliferative Effect of Specific Anti-EGFR Single Chain Antibody on Triple Negative Breast Cancer Cells.

Authors:  Forough Abdollahzadeh; Foroogh Nejatollahi
Journal:  Rep Biochem Mol Biol       Date:  2020-07

6.  LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA.

Authors:  Mingwei Chen; Xuedong Wei; Xiu Shi; Le Lu; Guangbo Zhang; Yuhua Huang; Jianquan Hou
Journal:  Cancer Biol Med       Date:  2021-03-12       Impact factor: 4.248

Review 7.  Long Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications.

Authors:  Qi-Yuan Huang; Guo-Feng Liu; Xian-Ling Qian; Li-Bo Tang; Qing-Yun Huang; Li-Xia Xiong
Journal:  Cancers (Basel)       Date:  2019-11-16       Impact factor: 6.639

8.  Sonographic Features of Triple-Negative Breast Carcinomas Are Correlated With mRNA-lncRNA Signatures and Risk of Tumor Recurrence.

Authors:  Jia-Wei Li; Jin Zhou; Zhao-Ting Shi; Na Li; Shi-Chong Zhou; Cai Chang
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

9.  Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis.

Authors:  Shuo Zhang; Feixia Ma; Xiaohong Xie; Yong Shen
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

10.  Long non-coding RNA-based signatures to improve prognostic prediction of breast cancer.

Authors:  Yi Zhang; Yuzhi Wang; Gang Tian; Tianhua Jiang
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.